Michael B. Liebowitz, M.D. is Associate Professor of Clinical Psychiatry at Columbia University, N.Y., Director of the Anxiety Disorders Clinic at the New York State Psychiatric Institute and Managing Director of the Medical Research Network. Dr. Liebowitz is recognized as one of the leading researchers in the field of anxiety disorders in the world. He is assisting us with the clinical development of our anxiety program.
Ellen Freeman, Ph.D. is Research Professor and Co-Director of the Human Behavior and Reproduction Unit in the Department of Obstetrics and Gynecology at the University of Pennsylvania. Dr. Freeman currently serves on the Health Behavior and Prevention Review Committee, National Institute of Mental Health and also serves as reviewer for numerous scientific and professional journals. Dr. Freeman is recognized internationally as one of the leading researchers in the field of PMS. She assists us with our clinical development program on premenstrual syndrome.
Roger Whiting, Ph.D. is the President and Chief Scientific Officer of Los Altos Therapeutics, LLC, a development stage pharmaceutical development company and has 29 years of experience in the pharmaceutical sector. At Syntex Corporation, Dr. Whiting held positions in pharmacology, and new drug discovery, evaluation and development. He was Senior Vice President and Head of the Neurobiology Business Unit at Roche Bioscience. He was president and Chief Executive Advisor of Roxro Pharmaceuticals before its present sale. He has published over 90 scientific papers and holds 15 patents. Dr. Whiting is advising us on new product development.
Gustavo A. García de la Mora, Ph.D. is Professor of Chemistry at the Faculty of Chemistry of the National Autonomous University of Mexico. He has over 30 years of experience in the synthesis of organic compounds - particularly steroids. He consults for the World Health Organization and several chemical companies. Dr. García de la Mora is guiding the synthesis of new pherines at pilot and industrial scales.
José Vicente Díaz-Sánchez, M.D., Ph.D. has held the position of Coordinator of the Pharmacokinetics Unit and the Infertility Unit at the National Institute of Nutrition, Department of Biology and Reproduction, in Mexico City. He has lectured and published extensively in the fields of endocrinology and contraception. The World Health Organization recently honored him for his collaborations on human reproduction. Dr. Díaz-Sánchez is studying the effects of pherines on the endocrine system.
Rita Hanover, Ph.D. has served as a consultant to Pherin Pharmaceuticals.